A wide variety of rheumatic diseases has been documented in the presence of hepatitis C virus (HCV) infection and in human immunodeficiency virus (HIV) infection. In this conditions, physicians are refrained from using corticosteroids and/or immunosuppressants agents because of the risk of favouring viral replication and the progression of the underlying viral disease. In the present review we have focused our attention on the possible role of cyclosporine A (CsA), anti-Tumour Necrosis Factor (TNF) alpha agents in the treatment of HIV or HCV infected autoimmune patients. The results drown from the literature and from our personal experience confirm the safety of CsA and anti-TNF alpha agents, in terms of viral load and liver toxicity. A limited experience also suggest that both therapies can be given in combination in rheumatoid arthritis patients without increasing the risk of adverse events
Treatment of rheumatic diseases in patients with HCV and HIV infection / M. Galeazzi, C. Giannitti, S. Manganelli, M. Benucci, S. Scarpato, C. Bazzani, R. Caporali, G. Sebastiani. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 8:2(2008), pp. 100-103.
Treatment of rheumatic diseases in patients with HCV and HIV infection
R. Caporali;
2008
Abstract
A wide variety of rheumatic diseases has been documented in the presence of hepatitis C virus (HCV) infection and in human immunodeficiency virus (HIV) infection. In this conditions, physicians are refrained from using corticosteroids and/or immunosuppressants agents because of the risk of favouring viral replication and the progression of the underlying viral disease. In the present review we have focused our attention on the possible role of cyclosporine A (CsA), anti-Tumour Necrosis Factor (TNF) alpha agents in the treatment of HIV or HCV infected autoimmune patients. The results drown from the literature and from our personal experience confirm the safety of CsA and anti-TNF alpha agents, in terms of viral load and liver toxicity. A limited experience also suggest that both therapies can be given in combination in rheumatoid arthritis patients without increasing the risk of adverse eventsFile | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S1568997208001213-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
162.24 kB
Formato
Adobe PDF
|
162.24 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.